Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
Pooled resultResult — go to the resultOdds ratio 0.84 95% CI 0.76–0.96Authors' conclusion
Bempedoic acid reduced non-fatal MI in patients with hyperlipidaemia, whereas it had no significant effect on stroke and all-cause mortality.
Study context
- Population
- Patients with hyperlipidaemia with an indication for lipid-lowering therapy
- Participants
- 18,200 patients10 trials
- Comparison
- Bempedoic acid vs placebo
- Bempedoic acidn = 9,765
- Placebon = 8,435reference
- Outcome
- Three-point MACE:
- CV death
- Non-fatal MI
- Non-fatal stroke
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
Odds ratio
0.84
95% CI 0.76–0.96
P < 0.001
Bempedoic acidvs Placebo
OR 0.84 (95% CI 0.76–0.96); P < 0.001
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| StrokeI2 = 0% | 0.86 (0.69–1.08) | P = 0.20 | |
| All-cause mortalityI2 = 18% | 1.19 (0.73–1.93) | P = 0.49 | |
| 0.512Odds ratio (log scale) |
Non-fatal myocardial infarction (MI)
- MACE reduction driven by a lower rate of non-fatal MI
Original publication
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 18 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →